{"id":"W3005265102","doi":"10.1200/jco.2020.38.4_suppl.518","title":"Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Pembrolizumab; Phases of clinical research; Adverse effect; Gastroenterology; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002336512,0.0006885979,0.001144766,0.0002948424,0.0002479496,0.0008434533,0.0006574653,0.0006937033,0.003645443],"category_scores_gemma":[0.00162282,0.0003567682,0.0007445719,0.0002987461,0.0003786646,0.0008046883,0.0003543235,0.001898856,0.0007050289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007298322,"about_ca_system_score_gemma":0.0007742211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000518135,"about_ca_topic_score_gemma":0.001009521,"domain_scores_codex":[0.9994547,0.0003054993,0.00003761102,0.00006843943,0.00007332786,0.00006042374],"domain_scores_gemma":[0.9988958,0.0002029144,0.000405219,0.0001061201,0.00008666801,0.0003032828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7332385,0.01976706,0.0195209,0.001905933,0.003164896,0.0004107405,0.000303441,0.003132403,0.043261,0.0003448223,0.01109442,0.1638558],"study_design_scores_gemma":[0.6598176,0.2496846,0.06643029,0.00008227474,0.003206256,0.001010271,0.00007048932,0.002247163,0.006891655,0.0002856994,0.01020509,0.00006852621],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986586,0.004650291,0.0007671249,0.0004750987,0.00008476689,0.001349454,0.003002138,0.0001607251,0.002924382],"genre_scores_gemma":[0.9880877,0.001587705,0.001411954,0.0006285763,0.0001338689,0.0009917113,0.00531392,0.00002946439,0.001814972],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003645443,"threshold_uncertainty_score":0.01235682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1042945061691365,"score_gpt":0.3754582938832818,"score_spread":0.2711637877141452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}